Answers are grounded in this paper and cite their sources.
Myeloid sarcoma (MS) is a rare neoplasm consisting of immature myeloid cells that forms a tumor mass at an anatomic site other than the bone marrow (BM). 1 MS may develop de novo or secondary to other types of myeloid neoplasm. MS is most often associated with acute myeloid leukemia (AML), and develops in 2–5% of AML patients. 2 , 3 Less frequently, MS can arise in patients with chronic myelogenous leukemia (CML), mainly in the setting of blast phase (BP) or accelerated phase (AP). 3 , 4 , 5 Traditionally, MS is considered the equivalent of AML, and is one of diagnostic criteria for CML-BP, regardless of the blast count in the BM or peripheral blood. According to the 2008 World Health Organization criteria, CML-BP can be diagnosed when: (1) blasts are ⩾ 20% in the BM or peripheral blood (medullary BP); or (2) there is an extramedullary blast proliferation, in other words, MS.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: